Clomid 50 mg

Clomid 50 mg contains clomiphene citrate, a prescription SERM. It is FDA-approved for the treatment of ovulatory dysfunction in women desiring pregnancy. In non-medical bodybuilding contexts, it is commonly referenced as a post-cycle therapy agent to help restore endogenous testosterone production, though such use is not approved and the FDA label states there are no adequate studies demonstrating effectiveness in male infertility .

In medical practice, the recommended dose is 50 mg daily for 5 days per cycle, starting on cycle day 3, 4, or 5. In non-medical male contexts, clomiphene is referenced at lower doses, commonly 25 mg/day, as investigated in a pilot study for hypogonadism.

Clomiphene citrate is a SERM that blocks estrogen receptors at the hypothalamus and pituitary, preventing the negative feedback of estrogen on gonadotropin secretion. This stimulates the release of FSH and LH, which in turn can stimulate ovulation in women and testosterone production in men.

In ovulation induction, ovulation typically occurs approximately 5 to 12 days after the last dose of clomiphene. The half-life of clomiphene has been reported as 5–7 days, with the less potent zuclomiphene isomer remaining detectable for longer .

Clomiphene citrate has a half-life of 5–7 days in some references, with the active enclomiphene isomer having this duration . One study reported a mean plasma half-life of 12 days for clomiphene, consistent with the closely related compound tamoxifen.

There is no universally "best" SERM. Clomiphene is commonly referenced in non-medical post-cycle therapy contexts, but Nolvadex (tamoxifen) is another SERM often used for similar purposes. The FDA label does not approve clomiphene for male infertility, and the choice between them, if any, depends on individual factors and clinical guidance.

Clomiphene and tamoxifen are both SERMs, but they have different tissue selectivity profiles and are used in different clinical contexts. Clomiphene is primarily used for ovulation induction, while tamoxifen is used for breast cancer treatment and is also referenced in non-medical post-cycle therapy. Both block estrogen receptors, but their effects vary by tissue.

Clomiphene is a SERM that blocks estrogen receptors, while Arimidex (anastrozole) is an aromatase inhibitor that reduces estrogen production. Both can affect the hypothalamic-pituitary-gonadal axis, but through different mechanisms. Clomiphene is commonly referenced for post-cycle therapy, while anastrozole is used for managing estrogenic side effects during cycles.

Medical clomiphene dosing for ovulation induction is 50 mg daily for 5 days per cycle. In non-medical male contexts, clomiphene is referenced at lower doses, commonly 25 mg/day. Clomid 50 mg is labeled at 50 mg per tablet.

Clomid 50 mg is labeled at 50 mg of clomiphene citrate per tablet. It is supplied in a 100-tablet package, giving 5,000 mg of total labeled clomiphene citrate content.

Yes. A published laboratory report dated January 13, 2026 measured Clomid 50 mg at 52.78 mg per tablet, equivalent to 105.56% of its 50 mg label claim. Complete reports can be viewed in the Lab Reports tab.

Yes. Visual symptoms including blurring, spots, flashes, photophobia, diplopia, scotomata, and phosphenes have been reported with clomiphene use. These symptoms increase in incidence with increasing total dose or therapy duration and may be irreversible, especially with increased dosage or duration. Patients should be warned that visual symptoms may render driving or operating machinery more hazardous.